Quoin Total Other Income Expense Net from 2010 to 2024

QNRX Stock  USD 0.66  0.07  9.59%   
Quoin Pharmaceuticals Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Quoin Pharmaceuticals Total Other Income Expense Net regression line of annual values had significance of  0.01 and arithmetic mean of  1,021,903. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
714.3 K
Current Value
750 K
Quarterly Volatility
879.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Quoin Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quoin Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 4 M, Total Revenue of 0.0 or Other Operating Expenses of 7 M, as well as many indicators such as Dividend Yield of 7.58, Ptb Ratio of 0.74 or Book Value Per Share of 5.97. Quoin financial statements analysis is a perfect complement when working with Quoin Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Quoin Pharmaceuticals Correlation against competitors.

Latest Quoin Pharmaceuticals' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Quoin Pharmaceuticals Ltd over the last few years. It is Quoin Pharmaceuticals' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Quoin Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Quoin Total Other Income Expense Net Regression Statistics

Arithmetic Mean1,021,903
Coefficient Of Variation86.07
Mean Deviation704,630
Median1,550,375
Standard Deviation879,545
Sample Variance773.6B
Range2.6M
R-Value(0.64)
Mean Square Error487.3B
R-Squared0.42
Significance0.01
Slope(126,714)
Total Sum of Squares10.8T

Quoin Total Other Income Expense Net History

2024750 K
2023714.3 K
2022-123.8 K
2021-1.1 M
2020-425.4 K

About Quoin Pharmaceuticals Financial Statements

Quoin Pharmaceuticals investors use historical fundamental indicators, such as Quoin Pharmaceuticals' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Quoin Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net714.3 K750 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.